2021
How to prevent and manage hyperammonemic encephalopathies in valproate therapy
Mitschek M, Vanicek T, Unterholzner J, Kraus C, Weidenauer A, Naderi-Heiden A, Frey R, Silberbauer L, Gryglewski G, Papageorgiou K, Winkler D, Dold M, Kasper S, Praschak-Rieder N, Bartova L. How to prevent and manage hyperammonemic encephalopathies in valproate therapy. Journal Of Affective Disorders Reports 2021, 5: 100186. DOI: 10.1016/j.jadr.2021.100186.Peer-Reviewed Case Reports and Technical NotesSevere cognitive impairmentValproic acidHyperammonemic encephalopathyPlasma levelsCognitive impairmentPotential drug interactionsYoung male patientLife-threatening symptomsUrea cycle deficiencyUrea cycle defectsValproate therapyMale patientsCase seriesFemale patientsUrinary levelsComatose stateDrug interactionsIndividual patientsPsychotic episodePatientsAffective symptomsCurrent psychotic episodePsychiatric inpatientsPolypharmacyEncephalopathy
2018
Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy
Spies M, James GM, Vraka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz GS, Nics L, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Winkler D. Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. Translational Psychiatry 2018, 8: 198. PMID: 30242221, PMCID: PMC6155094, DOI: 10.1038/s41398-018-0227-2.Peer-Reviewed Original ResearchConceptsBright light therapyMAO-A levelsBrain MAO-A levelsSeasonal affective disorderPositron emission tomographyMAO-A VTNon-seasonal depressionHealthy controlsLight therapyAffective disordersTreatment of SADMajor depressive disorderBrain monoamine oxidaseCerebral MAODepressive disorderSerotonergic systemPET scansHC groupMilder symptomsPatientsDistribution volumeEmission tomographyMonoamine oxidaseDisordersSignificant reductionStriatal dopaminergic alterations in Tourette’s syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies
Hienert M, Gryglewski G, Stamenkovic M, Kasper S, Lanzenberger R. Striatal dopaminergic alterations in Tourette’s syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies. Translational Psychiatry 2018, 8: 143. PMID: 30072700, PMCID: PMC6072751, DOI: 10.1038/s41398-018-0202-y.Peer-Reviewed Original ResearchConceptsTourette patientsTourette syndromeDopamine transporterDopaminergic alterationsDopamine systemCurrent pathophysiological hypothesesStriatal dopaminergic alterationsStriatal dopamine receptorsStudy population characteristicsStriatal dopamine transporterStriatal dopamine functionFree patientsHealthy controlsPathophysiological hypothesesDopamine receptorsMolecular imaging studiesNonsignificant trendDopamine functionPatientsSPECT studiesSystematic reviewImaging studiesSyndromeNeuroimaging studiesReceptor binding